Tonix Pharma Uplists to Nasdaq Global Select Market

Tonix Pharma ( (TNXP) ) has provided an announcement.

On March 3, 2026, Tonix Pharmaceuticals announced that Nasdaq approved the transfer of its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher-tier market commencing the same day under the ticker TNXP. The move acknowledges Tonix’s compliance with stricter financial and corporate governance standards and is expected to enhance its visibility, reputation and liquidity, potentially attracting more institutional investors and improving access to capital for future growth.

Management described the uplisting as an important milestone that may broaden market recognition among customers, partners and investors, signaling financial and operational progress to stakeholders. By joining Nasdaq’s highest market tier, Tonix positions itself alongside more established peers, which could support its efforts to build long-term shareholder value and strengthen its competitive standing in the biotechnology sector.

The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

The score is held down primarily by weak financial performance (losses and cash burn) and bearish technicals (below major moving averages with negative MACD). Positive corporate developments (commercial launch and regulatory/pipeline progress) provide support but do not fully offset the current profitability and trend risks; valuation is difficult to assess due to negative earnings.

To see Spark’s full report on TNXP stock, click here.

More about Tonix Pharma

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments addressing high unmet medical need. Its flagship approved medicine TONMYA treats fibromyalgia, complemented by marketed acute migraine drugs Zembrace SymTouch and Tosymra, and a pipeline that includes candidates for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis and kidney transplant rejection prevention.

The company leverages its CNS commercial infrastructure while advancing multiple Phase 2 and Phase 2–ready programs, though most pipeline assets remain investigational and unapproved for any indication. Tonix’s development strategy centers on expanding TONMYA’s potential indications and progressing monoclonal antibody and CD40 ligand inhibitor programs to strengthen its presence in both CNS and immunology markets.

Average Trading Volume: 438,601

Technical Sentiment Signal: Strong Sell

Current Market Cap: $178.8M

Learn more about TNXP stock on TipRanks’ Stock Analysis page.